12 studies on Glucagon receptor mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
The introduction of resmetirom and the proven efficacy of semaglutide represent a revolutionary shift in the treatment paradigm for MASH, moving beyond solely lifestyle interventions. These drugs offer the first speci…
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…